2-Chlor-α'-phenylmaleinsaeureimid | 4840-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-Chlor-α'-phenylmaleinsaeureimid
• 英文别名: 3-chloro-4-phenyl-1H-pyrrole-2,5-dione；3-chloro-4-phenyl-pyrrole-2,5-dione；3-chloro-4-phenylpyrrole-2,5-dione
• CAS: 4840-61-3
• 化学式: C₁₀H₆ClNO₂
• 分子量: 207.616
• InChiKey: KUKHGIHFGSRZCM-UHFFFAOYSA-N

物化性质

• 熔点：
  155-156 °C
• 沸点：
  361.1±42.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Chlor-α'-phenylmaleinsaeureimid 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 反应 72.0h， 生成 1-Methyl-3-phenyl-4-phenylamino-pyrrole-2,5-dione
  参考文献：
  名称：

  3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)

  摘要：

  Potent 3-anilino-4-arylmaleimide glycogen synthase kinase-3 (GSK-3) inhibitors have been prepared using automated array methodology. A number of these are highly selective, having little inhibitory potency against more than 20 other protein kinases. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00721-6
• 作为产物：
  描述：

  2-苯乙酰胺 在 草酰氯 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 2-Chlor-α'-phenylmaleinsaeureimid
  参考文献：
  名称：

  Synthesis of aryl anilinomaleimide based derivatives as glycogen synthase kinase-3β inhibitors with potential role as antidepressant agents

  摘要：

  基于新型苯胺马来酰亚胺衍生物被发现能抑制GSK-3β活性体外，并在动物模型中展现抗抑郁效果。

  DOI：

  10.1039/c5nj02896e

文献信息

• [EN] PLANT GROWTH REGULATION<br/>[FR] REGULATION DE LA CROISSANCE VEGETALE
  申请人：BAYER CROPSCIENCE GMBH

  公开号：WO2005107465A1

  公开（公告）日：2005-11-17

  The present invention relates to the use of a compound for plant growth regulation, preferably by application of the compound to plants, to the seeds from which they grow or to the locus in which they grow, in an effective plant growth regulating, preferably non-phytotoxic amount, which compound is a 3,4-disubstituted maleimide derivative of formula (I) or an agriculturally acceptable salt thereof, wherein: X is aryl or heteroaryl which groups are unsubstituted or substituted; Y is NH or a covalent bond; and Z is aryl or heteroaryl which groups are unsubstituted or substituted and a method for treatment of plants with such compounds in order to induce growth regulating responses.

  本发明涉及一种化合物用于植物生长调节，优选通过将该化合物施用于植物、它们生长的种子或它们生长的位置，以有效的植物生长调节，优选为非植物毒性量，该化合物是式(I)的3,4-二取代马来酰亚胺衍生物或其农业可接受的盐，其中：X是未取代或取代的芳基或杂环芳基；Y是NH或共价键；Z是未取代或取代的芳基或杂环芳基，以及使用这些化合物处理植物的方法，以诱导生长调节反应。
• Synthesis, Cytotoxicity and Protein Kinase C Inhibition of Arylpyrrolylmaleimides
  作者：Gui-Qing Xu、Chong Zhang、Lei Zhang、Xing-Lu Zhou、Bo Yang、Qiao-Jun He、Yong-Zhou Hu

  DOI：10.1002/ardp.200700190

  日期：2008.5

  novel arylpyrrolylmaleimides was synthesized and evaluated for their in‐vitro cytotoxicity against various human cancer cell lines and their protein‐kinase C inhibitory activity. Some of the compounds showed high or moderate cytotoxic activity against the tested cell lines. Compound 6b is the most promising compound against the tested cancer cell lines; 6d and 6e showed moderate protein‐kinase C inhibition

  合成了一系列新型芳基吡咯基马来酰亚胺，并评估了它们对各种人类癌细胞系的体外细胞毒性及其蛋白激酶 C 抑制活性。一些化合物对测试的细胞系显示出高或中度的细胞毒活性。化合物 6b 是最有前途的抗癌细胞系化合物；6d和6e显示出中度蛋白激酶C抑制。根据获得的实验数据讨论结构 - 活性关系。
• [EN] 3,4-DISUBSTITUTED MALEIMIDES FOR USE AS VASCULAR DAMAGING AGENTS<br/>[FR] MALEIMIDES 3,4-DISUBSTITUES UTILISES EN TANT QU'AGENTS DE DEGRADATION VASCULAIRE
  申请人：ASTRAZENECA AB

  公开号：WO2005102997A1

  公开（公告）日：2005-11-03

  This invention relates to novel compounds of Formula (I) for use as vascular damaging agents: Formula (I) wherein Rl, R7, R8, R9, ARI, AR2, AR3, p, q and r are as described in the specification. The invention also relates to methods for preparing compounds of Formula (I), to their use as medicaments (including methods for the treatment of angiogenesis or disease states associated with angiogenesis) and to pharmaceutical compositions containing compounds of Formula (I).

  本发明涉及用作血管损伤剂的新化合物的公式（I）：公式（I）其中Rl、R7、R8、R9、ARI、AR2、AR3、p、q和r如规范中所述。该发明还涉及制备公式（I）化合物的方法，它们作为药物的用途（包括用于治疗血管生成或与血管生成相关的疾病状态的方法）以及含有公式（I）化合物的药物组合物。
• [EN] PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR X DU FOIE A BASE DE DERIVES PYRROLE-,5-DIONE
  申请人：ASTRAZENECA AB

  公开号：WO2005005417A1

  公开（公告）日：2005-01-20

  The present invention relates to certain novel compounds of the Formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及某些新颖化合物的公式（I），以及制备这些化合物的方法，它们在调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）方面的用途，以及在治疗和/或预防包括心血管疾病（如动脉粥样硬化）、炎症性疾病、阿尔茨海默病、脂质紊乱（失调脂质）以及与胰岛素抵抗、2型糖尿病和代谢综合征其他表现相关与否的临床病症方面的用途，以及它们的治疗用途的方法和含有它们的药物组合物。
• [EN] PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS<br/>[FR] DERIVES DE PYRROLE-2, 5-DITHIONE UTILISES COMME MODULATEURS DU RECEPTEUR X HEPATIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2005005416A1

  公开（公告）日：2005-01-20

  The present invention relates to certain novel compounds of the Formula I to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer´s disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及一些新颖的化合物，其化学式为I，涉及制备这些化合物的方法，以及它们在调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）方面的用途，以及用于治疗心血管疾病（如动脉粥样硬化）、炎症性疾病、阿尔茨海默病、脂质紊乱（失调脂质）是否与胰岛素抵抗有关、2型糖尿病和代谢综合征其他表现的临床病症，以及用于其治疗的方法和含有它们的药物组合物。